Q4 2025 Holdings
Filed 2026-02-17 | 22 holdings | $494.0M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Stoke Therapeutics Inc(STOK) | COM | 86150R107 | $171.5M | 5,404,674 | 34.7% |
| GH Research PLC(GHRS) | ORDINARY SHARES | G3855L106 | $132.2M | 10,406,575 | 26.8% |
| Cullinan Therapeutics Inc(CGEM) | COM | 230031106 | $92.8M | 8,963,500 | 18.8% |
| Denali Therapeutics Inc(DNLI) | COM | 24823R105 | $28.7M | 1,738,750 | 5.8% |
| C4 Therapeutics Inc(CCCC) | COM STK | 12529R107 | $13.6M | 7,098,133 | 2.7% |
| Xencor Inc(XNCR) | COM | 98401F105 | $10.8M | 705,558 | 2.2% |
| Immatics N.v(IMTX) | SHS | N44445109 | $9.7M | 921,950 | 2.0% |
| Tscan Therapeutics Inc(TCRX) | COM | 89854M101 | $8.0M | 8,019,148 | 1.6% |
| Passage BIO Inc(PASG) | COM NEW | 702712209 | $7.4M | 623,704 | 1.5% |
| Korro BIO Inc(KRRO) | COM | 500946108 | $5.4M | 677,915 | 1.1% |
| Precision Biosciences Inc(DTIL) | COM NEW | 74019P207 | $4.1M | 993,913 | 0.8% |
| Neuphoria Therapeutics Inc(NEUP) | COM | 64136E102 | $3.4M | 875,228 | 0.7% |
| Agios Pharmaceuticals Inc(AGIO) | COM | 00847X104 | $2.2M | 79,624 | 0.4% |
| CG Oncology Inc(CGON) | COM | 156944100 | $1.3M | 31,591 | 0.3% |
| Arrowhead Pharmaceuticals in(ARWR) | COM | 04280A100 | $799.5K | 12,043 | 0.2% |
| Design Therapeutics Inc(DSGN) | COM | 25056L103 | $652.1K | 69,516 | 0.1% |
| Entrada Therapeutics Inc(TRDA) | COM | 29384C108 | $531.4K | 51,689 | 0.1% |
| Werewolf Therapeutics Inc(HOWL) | COM | 95075A107 | $415.5K | 655,926 | 0.1% |
| Maplight Therapeutics Inc(MPLT) | COM | 56565P103 | $236.7K | 13,477 | 0.0% |
| Generation BIO Co | COM NEW | 37148K209 | $142.0K | 25,000 | 0.0% |
| Proqr Thrapeutics N V | SHS EURO | N71542109 | $138.3K | 68,486 | 0.0% |
| Applied Therapeutics Inc(APLT) | COM | 03828A101 | $41.1K | 410,500 | 0.0% |